This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016
Practice Guidelines for Treatment of Chronic Hepatitis B (1) and update the previous …

Importance More than 240 million individuals worldwide are infected with chronic hepatitis B
virus (HBV). Among individuals with chronic HBV infection who are untreated, 15% to 40 …

Background and Aims Cancer‐associated fibroblasts (CAFs) are key players in multicellular,
stromal‐dependent alterations leading to HCC pathogenesis. However, the intricate …

Chronic HBV infection is a global public health burden estimated to impact nearly 300
million persons worldwide. Despite the advent of potent antiviral agents that effectively …

A<fc>ASLD</fc> guidelines for treatment of chronic hepatitis <fc>B</fc> Page 1 PRACTICE
GUIDELINE AASLD Guidelines for Treatment of Chronic Hepatitis B Norah A. Terrault,1 Natalie …

Background Few data are available regarding the use of tenofovir disoproxil fumarate (TDF)
during pregnancy for the prevention of mother-to-child transmission of hepatitis B virus …

Background The novel prodrug tenofovir alafenamide delivers the nucleotide reverse
transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir …

Since active hepatitis B virus (HBV) replication is the key driver of hepatic necroinflammation
and disease progression, the treatment aim of chronic hepatitis B (CHB) is to suppress HBV …

Background Tenofovir alafenamide is a novel prodrug formulated to deliver the active
metabolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose …

Chronic infection with hepatitis B virus (HBV) greatly increases the risk for liver cirrhosis and
hepatocellular carcinoma (HCC). HBV isolates worldwide can be divided into ten genotypes …